研究業績 – 大阪大学大学院医学系研究科消化器内科学

2025年

Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.Tahata Y, Hikita H, Takaki A, Kurosaki M, Matsuura K, Yatsuhashi H, Kuroda H, Ueno Y, Maekawa S, Nakamura M, Sakamori R, Kodama T, Takehara T.J Gastroenterol. 2025 Oct 30. in press.
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinomaMaesaka K, Hikita H, Tahata Y, Nishioka C, Kai M, Shirai K, Murai K, Makino Y, Saito Y, Kodama T, Ohkawa K, Miyazaki M, Nozaki Y, Yakushijin T, Sakamori R, Tatsumi N, Matsumoto K, Ishida H, Iio S, Nawa T, Kakita N, Nakahara M, Hosui A, Yoshida Y, Usui T, Imanaka K, Doi Y, Sakakibara M, Takehara T.J Gastroenterol. 2025 Oct 25. in press.
Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection.Adachi Y, Hayashi Y, Yoneda S, Tajiri A, Fukuda H, Kimura E, Nakagawa K, Saiki H, Uema R, Yoshihara T, Tsujii Y, Takehara T.Int J Clin Oncol. 2025 Dec;30(12):2567-2575.
First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).Watabe T, Mukai K, Naka S, Sasaki H, Kamiya T, Hayakawa T, Fukuhara A, Takano T, Shirakami Y, Ooe K, Shigeno S, Okamura S, Masumura K, Hida E, Haba H, Toyoshima A, Isohashi K, Shimomura I, Tomiyama N.J Nucl Med. 2025 Sep 25:jnumed.125.270810.
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus EliminationMyojin Y, Hikita H, Tahata Y, Fukumoto K, Kato S, Sasaki Y, Kumazaki S, Tsuchiya A, Enomoto M, Miki D, Yatsuhashi H, Kuroda H, Uchida Y, Yoshiji H, Yamashita T, Mawatari S, Tamaki N, Miyaaki H, Asahina Y, Suda G, Matsuura K, Nakamoto Y, Hiasa Y, Takami T, Shirai K, Maesaka K, Murai K, Makino Y, Saito Y, Kodama T, Tatsumi T, Takehara T.Hepatol Res. 2025 Sep 18. in press.
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular CarcinomaMaesaka K, Hikita H, Kai M, Tahata Y, Shirai K, Doi A, Murai K, Saito Y, Yamada R, Kodama T, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Tatsumi N, Iio S, Nawa T, Kakita N, Nakahara M, Hosui A, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Tatsumi T, Takehara T.J Gastroenterol Hepatol. 2025 Oct;40(10):2580-2590.
Safety and effectiveness of oral budesonide after endoscopic balloon dilation in patients with Crohn's disease : A multicenter prospective intervention studyOtake-Kasamoto Y, Yoshihara T, Shinzaki S, Yamada T, Ogawa H, Sakakibara Y, Hiyama S, Tsujii Y, Asakura A, Tashiro T, Amano T, Tani M, Uema R, Tsujii Y, Inoue T, Iijima H, Hayashi Y, Takehara T.Inflamm Intest Dis. 2025;10:254-264.
The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide AnalogsMurai K, Hikita H, Yamada R, Nishimura Y, Miyazaki M, Ishida H, Hosui A, Sakamori R, Tatsumi N, Ohkawa K, Doi Y, Nawa T, Egawa S, Yoshida Y, Nozaki Y, Imanaka K, Nakahara M, Sakakibara M, Yakushijin T, Ogawa H, Usui T, Matsumoto K, Oze T, Kuriki S, Sometani E, Jihyun Sung, Shimoda A, Shigeno S, Maesaka K, Shirai K, Doi A, Tahata Y, Saito Y, Kodama T, Tatsumi T, Yamada T, Takehara T.Hepatol Res. 2025 Sep;55(9):1228-1238.
Optimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter StudyAmano T, Yoshihara T, Nishida T, Sakakibara Y, Yamada T, Hiyama S, Murayama Y, Osugi N, Ogiyama H, Nagaike K, Arimoto Y, Kawai S, Yamaguchi T, Kitamura S, Ogawa H, Egawa S, Ishii S, Kizu T, Komori M, Tsujii Y, Asakura A, Tashiro T, Tani M, Otake-Kasamoto Y, Uema R, Tsujii Y, Inoue T, Shinzaki S, Iijima H, Hayashi Y, Takehara T.Crohns Colitis 360. 2025 May 30;7(3):otaf038.
p53 Deficiency in Colon Cancer Cells Promotes Tumor Progression Through the Modulation of Meflin in FibroblastsKimura E, Hayashi Y, Nakagawa K, Saiki H, Kato M, Uema R, Inoue T, Yoshihara T, Sakatani A, Fukuda H, Tajiri A, Adachi Y, Murai K, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.Cancer Sci. 2025 Jul;116(7):1871-1882.
Leucine-rich Alpha-2 glycoprotein could be clinically useful in active and postoperative Crohn’s diseaseTashiro T, Shinzaki S, Yoshihara T, Tsujii Y, Asakura A, Amano T, Tani M, Otake-Kasamoto Y, Uema R, Tsujii Y, Inoue T, Ogino T, Iijima H, Hayashi Y, Takehara T.Sci Rep. 2025 Mar 16;15(1):9031.
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinomaShiode Y, Kodama T, Sato Y, Takahashi R, Matsumae T, Shirai K, Doi A, Tahata Y, Hikita H, Tatsumi T, Fukai M, Taketomi A, Ruchirawat M, Wang XW, Takehara T.Biomark Res. 2025 Mar 4;13(1):37.
Low skeletal muscle mass contributes to the prognosis of patients with superficial esophageal cancer treated with definitive chemoradiotherapyNakagawa K, Hayashi Y, Adachi Y, Tajiri A, Fukuda H, Kimura E, Uema R, Saiki H, Kato M, Inoue T, Yoshihara T, Yoshii S, Tsujii Y, Takehara T.Esophagus. 2025 Apr;22(2):198-206.
Utility and clinical significance of endoscopic ultrasound-guided tissue acquisition for diagnosing lymphadenopathies in biliary tract cancerSato K, Shigekawa M, Yamamoto S, Matsumae T, Sato Y, Yoshioka T, Kodama T, Hikita H, Tatsumi T, Takehara T.Sci Rep. 2025 Jan 27;15(1):3363.
Feasibility and safety of endoscopic submucosal dissection for superficial cancer of the remnant esophagus after esophagectomyTsujii Y, Hayashi Y, Uema R, Saiki H, Kimura E, Nakagawa K, Fukuda H, Tajiri A, Adachi Y, Yoshihara T, Inoue T, Kato M, Yoshii S, Suzuki M, Makino T, Takehara T.Esophagus. 2025 Apr;22(2):148-156.
A rare case of a malignant hepatic perivascular epithelioid cell tumor (PEComa) with aggressive progression following the relapse of renal pecoma despite everolimus therapyKitagawa A, Nishio A, Hikita H, Kato T, Doi A, Sato K, Tahara S, Kimura Y, Ono Y, Takehara T.Clin J Gastroenterol. 2025 Apr;18(2):343-351.
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matchingYoshihara T, Amano T, Shinzaki S, Tsujii Y, Asakura A, Tashiro T, Tani M, Otake-Kasamoto Y, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Kitamura T, Kato M, Tsujii Y, Inoue T, Iijima H, Hayashi Y, Takehara T.Sci Rep. 2025 Jan 2;15(1):68.
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case ReportDaiku K, Nishio A, Hikita H, Doi A, Hayashi K, Kato S, Sasaki Y, Shimoda A, Kudo S, Fukumoto K, Maesaka K, Matsumae T, Shirai K, Sato K, Murai K, Tahata Y, Yoshioka T, Furuta K, Kodama T, Tatsumi T, Ogawa K, Takehara T.Gastro Hep Adv. 2025 Feb 1;4(5):100634.
Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis BShigeno S, Kodama T, Murai K, Motooka D, Fukushima A, Nishio A, Hikita H, Tatsumi T, Okamoto T, Kanto T, Takehara T.Cell Mol Gastroenterol Hepatol. 2025;19(1):101412.

2024年

Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel diseaseAmano T, Yoshihara T, Shinzaki S, Sakakibara Y, Yamada T, Osugi N, Hiyama S, Murayama Y, Nagaike K, Ogiyama H, Yamaguchi T, Arimoto Y, Kobayashi I, Kawai S, Egawa S, Kizu T, Komori M, Tsujii Y, Asakura A, Tashiro T, Tani M, Otake-Kasamoto Y, Uema R, Kato M, Tsujii Y, Inoue T, Yamada T, Kitamura T, Yonezawa A, Iijima H, Hayashi Y, Takehara T.Sci Rep. 2024 Nov 29;14(1):29755.
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy.Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, Miki D, Kurosaki M, Yoshiji H, Sakamori R, Kuroda H, Yatsuhashi H, Yamashita T, Hiasa Y, Kato N, Miyaaki H, Ueno Y, Itoh Y, Matsuura K, Takami T, Asahina Y, Suda G, Akuta N, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Miyazaki M, Nozaki Y, Sobue S, Yano H, Miyaki T, Moriuchi A, Hori T, Shirai K, Murai K, Saito Y, Kodama T, Tatsumi T, Yamada T, Takehara T.Hepatol Res. 2024 Oct 29. in press.
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.Sometani E, Hikita H, Murai K, Toyoda H, Tanaka S, Oze T, Sung J, Shimoda A, Fukuoka M, Shigeno S, Fukutomi K, Shirai K, Tahata Y, Saito Y, Nishio A, Furuta K, Kodama T, Sakamori R, Tatsumi T, Mita E, Umezawa A, Tanaka Y, Takehara T.Hepatol Res. 2024 Sep 18. in press.
Development of a hepatic differentiation method in 2D culture from primary human hepatocyte-derived organoids for pharmaceutical research.Ueyama-Toba Y, Tong Y, Yokota J, Murai K, Hikita H, Eguchi H, Takehara T, Mizuguchi H.iScience. 2024 Aug 22;27(9):110778.
Collaborative orchestration of BH3-only proteins governs Bak/Bax-dependent hepatocyte apoptosis under antiapoptotic protein-deficiency in miceKudo S, Hikita H, Saito Y, Murai K, Kodama T, Tatsumi T, Takehara T.Cell Death Differ. 2025 Jun;32(6):1153-1166.
A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy.Furuse J, Ikeda M, Ueno M, Furukawa M, Morizane C, Takehara T, Nishina T, Todaka A, Okano N, Hara K, Nakai Y, Ohkawa K, Sasaki T, Sugimori K, Yokoyama N, Yamamoto K.Clin Cancer Res. 2024 Sep 13;30(18):3990-3995.
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis.Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, Sakane S, Murai K, Sasaki Y, Shirai K, Saito Y, Kodama T, Kakita N, Takahashi H, Toyoda H, Suda G, Morii E, Kojima T, Ebihara T, Shimizu K, Sasaki Y, Tatsumi T, Takehara T.Aliment Pharmacol Ther. 2024 Aug;60(3):327-339.
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, Kakita N, Yamada Y, Toyoda H, Takahashi H, Suda G, Kai M, Tahata Y, Sakamori R, Kumazaki S, Fukumoto K, Myojin Y, Murai K, Kodama T, Tatsumi T, Tomonaga T, Sakamoto N, Morii E, Takehara T.Hepatol Commun. 2024 Jun 3;8(6):e0448.
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis.Sato K, Hikita H, Shigekawa M, Soma K, Yamauchi R, Sung J, Kato S, Sasaki Y, Kudo S, Fukumoto K, Shirai K, Murai K, Tahata Y, Yoshioka T, Nishio A, Saito Y, Kodama T, Sasaki Y, Tatsumi T, Takehara T.Sci Rep. 2024 May 26;14(1):12028.
A machine learning model for predicting the lymph node metastasis of early gastric cancer not meeting the endoscopic curability criteria.Kato M, Hayashi Y, Uema R, Kanesaka T, Yamaguchi S, Maekawa A, Yamada T, Yamamoto M, Kitamura S, Inoue T, Yamamoto S, Kizu T, Takeda R, Ogiyama H, Yamamoto K, Aoi K, Nagaike K, Sasai Y, Egawa S, Akamatsu H, Ogawa H, Komori M, Akihiro N, Yoshihara T, Tsujii Y, Takehara T.Gastric Cancer. 2024 Sep;27(5):1069-1077.
A novel artificial intelligence–based endoscopic ultrasonography diagnostic system for diagnosing the invasion depth of early gastric cancer.Uema R, Hayashi Y, Kizu T, Igura T, Ogiyama H, Yamada T, Takeda R, Nagai K, Inoue T, Yamamoto M, Yamaguchi S, Kanesaka T, Yoshihara T, Kato M, Yoshii S, Tsujii Y, Shinzaki S, Takehara T.J Gastroenterol. 2024 Jul;59(7):543-555.
High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.Tajiri A, Tsujii Y, Nishida T, Inoue T, Maekawa A, Kitamura S, Yamaguchi S, Nishihara A, Yamada T, Ogiyama H, Murayama Y, Yamamoto S, Egawa S, Uema R, Yoshihara T, Hayashi Y, Takehara T.Cancer Med. 2024 May;13(9):e7242.
Lysophosphatidylserines derived from microbiota in Crohn's disease elicit pathological Th1 response.Otake-Kasamoto Y, Kayama H, Kishikawa T, Shinzaki S, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T.J Exp Med. 2022 Jul 4;219(7):e20211291.
Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer.Yano T, Hayashi Y, Ishihara R, Iijima K, Iwakiri K, Uesato M, Oyama T, Katada C, Kawada K, Kushima R, Tateishi Y, Fujii S, Manabe N, Minami H, Kawakubo H, Tsubosa Y, Yamamoto S, Kadota T, Minashi K, Takeuchi H, Doki Y, Muto M.Esophagus. 2024 Apr;21(2):85-94.
The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary mucinous neoplasia.Yoshioka T, Shigekawa M, Ikezawa K, Hirao M, Ishii S, Suda T, Kegasawa T, Matsumoto K, Iwahashi K, Murata J, Kaneko A, Nakazuru S, Yamamoto S, Matsumae T, Kozumi K, Sato Y, Okabe J, Sato K, Hikita H, Sakamori R, Tatsumi T, Takehara T.Pancreatology. 2024 Feb;24(1):73-77.
Genome-wide loss-of-function genetic screen identifies INSIG2 as the vulnerability of hepatitis B virus-integrated hepatoma cells.Fukuoka M, Kodama T, Murai K, Hikita H, Sometani E, Sung J, Shimoda A, Shigeno S, Motooka D, Nishio A, Furuta K, Tatsumi T, Yusa K, Takehara T.Cancer Sci. 2024 Mar;115(3):859-870.
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T.PLoS One. 2024 Jan 2;19(1):e0294590.
Endoscopic features of synchronous multiple early gastric cancers: Findings from a nationwide cohort.Hayashi Y, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, Tsuji S, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Kurakami H, Fujishiro M, Masamune A, Takehara T.Digestion. 2024;105(4):266-279.

2023年

The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan – a multicenter collaborative observational study.Murai K, Hikita H, Kodama T, Kaibori M, Nishimura Y, Tatsumi T, Yamada T, Kanto T, Mochida S, Takehara T.Hepatol Res. 2024 May;54(5):439-450.
Non-Pure Intestinal Phenotype as an Indicator of Progression in Sporadic Nonampullary Duodenal Adenomas: A Multicenter Retrospective Cohort Study.Uema R, Hayashi Y, Komori M, Shibukawa N, Hayashi N, Horimoto M, Yamada T, Yamamoto M, Hiyama S, Kinoshita K, Ogiyama H, Yamaguchi S, Egawa S, Kanesaka T, Kato M, Yoshii S, Tsujii Y, Keiichiro H, Shinzaki S, Iijima H, Morii E, Takehara T.Clin Transl Gastroenterol. 2024 Jan 1;15(1):e00649.
Endoscopic submucosal dissection for early gastric cancer in a patient after left ventricular assist device implantation: A case report.Kuriki S, Tsujii Y, Saiki H, Amano T, Uema R, Kato M, Yoshihara T, Hayashi Y, Hikita H, Takehara T.DEN Open. 2023 Nov 14;4(1):e316.
The apelin-apelin receptor signaling pathway in fibroblasts is involved in tumor growth via p53 expression of cancer cells.Saiki H, Hayashi Y, Yoshii S, Kimura E, Nakagawa K, Kato M, Uema R, Inoue T, Sakatani A, Yoshihara T, Tsujii Y, Shinzaki S, Iijima H, Takehara T.Int J Oncol. 2023 Dec;63(6):139.
Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8+ T cell quality.Takahama S, Yoshio S, Masuta Y, Murakami H, Sakamori R, Kaneko S, Honda T, Murakawa M, Sugiyama M, Kurosaki M, Asahina Y, Takehara T, Appay V, Kanto T, Yamamoto T.Front Immunol. 2023 Oct 18;14:1257113.
Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, Miki D, Kurosaki M, Hiasa Y, Sakamori R, Kawada N, Yamashita T, Suda G, Yatsuhashi H, Yoshiji H, Kato N, Takami T, Nakao K, Matsuura K, Asahina Y, Itoh Y, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Ueno Y, Akuta N, Miyazaki M, Nozaki Y, Kabayama M, Sobue S, Moriuchi A, Miyaki T, Kodama T, Tatsumi T, Yamada T, Takehara T.J Gastroenterol. 2023 Dec;58(12):1211-1221.
Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.Okabe J, Kodama T, Sato Y, Shigeno S, Matsumae T, Daiku K, Sato K, Yoshioka T, Shigekawa M, Higashiguchi M, Kobayashi S, Hikita H, Tatsumi T, Okamoto T, Satoh T, Eguchi H, Akira S, Takehara T.J Exp Clin Cancer Res. 2023 Oct 9;42(1):262.
A novel role for Helicobacter pylori cytotoxin-associated gene A in negative regulation of autophagy in human gastric cells.Sakatani A, Hayashi Y, Saiki H, Kato M, Uema R, Inoue T, Kimura K, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.BMC Gastroenterol. 2023 Sep 22;23(1):326.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, doubleblind, active-controlled, randomised, phase 2b trial.Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group.Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802.
Efficacy and associated factors of endoscopic transpapillary drainage for postoperative biliary leakage.Murata J, Shigekawa M, Ishii S, Suda T, Ikezawa K, Hirao M, Matsumoto K, Kegasawa T, Iwahashi K, Iio S, Nakanishi F, Nakazuru S, Yoshida Y, Yamai T, Sato K, Yoshioka T, Hikita H, Tatsumi T, Takehara T.DEN Open. 2023 Aug 17;4(1):e281.
Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial.Otake-Kasamoto Y, Shinzaki S, Hiyama S, Tashiro T, Amano T, Tani M, Yoshihara T, Inoue T, Kawai S, Yoshii S, Tsujii Y, Hayashi Y, Iijima H, Takehara T.PLoS One. 2023 Aug 17;18(8):e0290329.
Endoscopic lesions of postoperative anastomotic area in patients with Crohn's disease in the biologic era: A Japanese multi-center nationwide cohort study.Ueda T, Koyama F, Sugita A, Ikeuchi H, Futami K, Fukushima K, Nezu R, Iijima H, Mizushima T, Itabashi M, Watanabe K, Hata K, Shinagawa T, Matsuoka K, Takenaka K, Sasaki M, Nagayama M, Yamamoto H, Shinozaki M, Fujiya M, Kato J, Ueno Y, Tanaka S, Okita Y, Hashimoto Y, Kobayashi T, Koganei K, Uchino M, Fujii H, Suzuki Y, Hisamatsu T.J Crohns Colitis. 2023 Dec 30;17(12):1968-1979.
Concomitant Clostridioides difficile and Edwardsiella tarda Infection in a Patient with Ulcerative Colitis.Fukuda H, Shinzaki S, Doi A, Yoshii S, Yoshioka T, Tsujii Y, Inoue T, Sakamori R, Takehara T.Intern Med. 2023 Jun 15;62(12):1757-1763.
HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes.Uehara S, Higuchi Y, Yoneda N, Ito R, Takahashi T, Murayama N, Yamazaki H, Murai K, Hikita H, Takehara T, Suemizu H.Biochem Biophys Res Commun. 2023 Jun 30;663:132-141.
Seasonal variations in gut microbiota and disease course in patients with inflammatory bowel disease.Tani M, Shinzaki S, Asakura A, Tashiro T, Amano T, Otake-Kasamoto Y, Yoshihara T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Motooka D, Nakamura S, Iijima H, Takehara T.PLoS One. 2023 Apr 18;18(4):e0283880.
Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.Teranishi R, Takahashi T, Nishida T, Kurokawa Y, Nakajima K, Koh M, Nishigaki T, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Motoori M, Omori T, Hirota S, Hayashi Y, Takehara T, Eguchi H, Doki Y.Int J Clin Oncol. 2023 May;28(5):680-687.
Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta-analyses.Yoshihara T, Shinzaki S, Iijima H, Tsujii Y, Hayashi Y, Takehara T.J Gastroenterol Hepatol. 2023 May;38(5):830-832.
Endoscopic features and clinical course of colorectal carcinoma resected by cold snare polypectomy.Yoshii S, Hayashi Y, Nakamura T, Nishiyama O, Nagaike K, Nakamatsu D, Yamada T, Egawa S, Ogiyama H, Yamaguchi S, Inoue T, Uema R, Kato M, Inoue T, Tsujii Y, Shinzaki S, Iijima H, Michida T, Morii E, Takehara T.J Gastroenterol Hepatol. 2023 Jun;38(6):948-954.
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T.PLoS One. 2023 Feb 7;18(2):e0281459.
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.Matsumae T, Kodama T, Tahata Y, Myojin Y, Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, Morishita N, Ohkawa K, Hijioka T, Sakakibara M, Doi Y, Kakita N, Yakushijin T, Sakamori R, Hikita H, Tatsumi T, Takehara T.Cancers (Basel). 2023 Jan 11;15(2):463.
Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey.Nakase H, Wagatsuma K, Nojima M, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Takeuchi K, Tamura S, Kinjo F, Ueno N, Naganuma M, Watanabe K, Moroi R, Nishimata N, Motoya S, Kurahara K, Takahashi S, Maemoto A, Sakuraba H, Saruta M, Tominaga K, Hisabe T, Tanaka H, Terai S, Hiraoka S, Takedomi H, Narimatsu K, Endo K, Nakamura M, Hisamatsu T.J Gastroenterol. 2023 Mar;58(3):205-216.

2022年

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.Tahata Y, Sakamori R, Maesaka K, Doi A, Yamada R, Kodama T, Hikita H, Miyazaki M, Nozaki Y, Kaneko A, Oshita M, Tanaka S, Imanaka K, Hiramatsu N, Morishita N, Ohkawa K, Yakushijin T, Sakakibara M, Iio S, Doi Y, Tatsumi T, Takehara T.Hepatol Res. 2023 Apr;53(4):301-311.
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T.PLoS One. 2022 Dec 21;17(12):e0279416.
Diagnostic value of endoscopic ultrasonography for the depth of gastric cancer suspected of submucosal invasion: a multicenter prospective study.Tsujii Y, Hayashi Y, Ishihara R, Yamaguchi S, Yamamoto M, Inoue T, Nagai K, Ogiyama H, Yamada T, Nakahara M, Kizu T, Kanesaka T, Matsuura N, Ohta T, Nakamatsu D, Yoshii S, Shinzaki S, Nishida T, Iijima H, Takehara T.Surg Endosc. 2023 Apr;37(4):3018-3028.
Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Oshita M, Imai Y, Hiramatsu N, Mita E, Kaneko A, Miyazaki M, Ohkawa K, Hijioka T, Fukui H, Ito T, Yamamoto K, Doi Y, Yoshida Y, Yamada Y, Yakushijin T, Tatsumi T, Takehara T; Osaka Liver Forum.Dig Dis Sci. 2023 May;68(5):2115-2122.
Ulcerative colitis-associated flat-appearing rectal cancer with submucosal extension.Sakamoto T, Yoshii S, Tsujii Y, Shinzaki S, Takehara T.Gastrointest Endosc. 2022 Dec;96(6):1085-1086.
Prokaryotic and viral genomes recovered from 787 Japanese gut metagenomes revealed microbial features linked to diets, populations, and diseases.Tomofuji Y, Kishikawa T, Maeda Y, Ogawa K, Otake-Kasamoto Y, Kawabata S, Nii T, Okuno T, Oguro-Igashira E, Kinoshita M, Takagaki M, Oyama N, Todo K, Yamamoto K, Sonehara K, Yagita M, Hosokawa A, Motooka D, Matsumoto Y, Matsuoka H, Yoshimura M, Ohshima S, Shinzaki S, Nakamura S, Iijima H, Inohara H, Kishima H, Takehara T, Mochizuki H, Takeda K, Kumanogoh A, Okada Y.Cell Genom. 2022 Nov 30;2(12):100219.
Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss.Sato K, Hikita H, Shigekawa M, Kato S, Sasaki Y, Shinkai K, Fukuoka M, Kudo S, Sato Y, Fukumoto K, Shirai K, Myojin Y, Sakane S, Murai K, Yoshioka T, Nishio A, Kodama T, Sakamori R, Tatsumi T, Takehara T.Cancer Sci. 2022 Dec;113(12):4311-4326.
Duodenal diverticulum metastasis from pulmonary squamous cell carcinoma diagnosed by EUS-FNA.Sunaga K, Yoshioka T, Shigekawa M, Sato K, Sakamori R, Tatsumi T, Ukon K, Morii E, Takehara T.Clin J Gastroenterol. 2022 Dec;15(6):1061-1066.
Gastric carcinoma with lymphoid stroma partially differentiated into squamous cell carcinoma.Inoue T, Hayashi Y, Tsujii Y, Yoshii S, Takehara T.Gastrointest Endosc. 2022 Sep;96(3):564-565.
Endoscopic submucosal dissection in the right lateral position for early gastric cancer in the fornix.Fukuda H, Tsujii Y, Kato M, Hayashi Y, Takehara T.VideoGIE. 2022 Aug 5;7(9):327-330.
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, Kanto T, Mizokami M.Glob Health Med. 2022 Aug 31;4(4):216-224.
Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan.Takehara T, Izumi N, Mochida S, Genda T, Fujiyama S, Notsumata K, Tamori A, Suzuki F, Suri V, Mercier RC, Matsuda T, Matsuda K, Kato N, Chayama K, Kumada H.Hepatol Res. 2022 Oct;52(10):833-840.
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, Motooka D, Sawai Y, Oshita M, Nakabori T, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T.Cancers (Basel). 2022 Jul 11;14(14):3367.
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Nozaki Y, Oshita M, Hiramatsu N, Miyazaki M, Mita E, Yamamoto K, Ohkawa K, Kaneko A, Ito T, Doi Y, Yakushijin T, Hijioka T, Fukui H, Imanaka K, Yoshida Y, Yamada Y, Tatsumi T, Takehara T.Hepatol Res. 2022 Oct;52(10):824-832.
Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.Shirai K, Hikita H, Sakane S, Narumi R, Adachi J, Doi A, Tanaka S, Tahata Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Mita E, Tomonaga T, Takehara T.PLoS One. 2022 Jul 7;17(7):e0271020.
Cerebellopontine angle metastasis of a neuroendocrine tumor mimicking vestibular schwannoma: A case report.Yamada S, Kijima N, Kinoshita M, Shinzaki S, Sato K, Kido K, Hirayama R, Kagawa N, Takehara T, Morii E, Kishima H.Surg Neurol Int. 2022 Jun 23;13:264.
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.Murai H, Kodama T, Maesaka K, Tange S, Motooka D, Suzuki Y, Shigematsu Y, Inamura K, Mise Y, Saiura A, Ono Y, Takahashi Y, Kawasaki Y, Iino S, Kobayashi S, Idogawa M, Tokino T, Hashidate-Yoshida T, Shindou H, Miyazaki M, Imai Y, Tanaka S, Mita E, Ohkawa K, Hikita H, Sakamori R, Tatsumi T, Eguchi H, Morii E, Takehara T.Hepatology. 2023 Jan 1;77(1):77-91.
Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non-Cell Autonomous Liver Carcinogenesis.Makino Y, Hikita H, Fukumoto K, Sung JH, Sakano Y, Murai K, Sakane S, Kodama T, Sakamori R, Kondo J, Kobayashi S, Tatsumi T, Takehara T.Cancer Res. 2022 Aug 16;82(16):2860-2873.
"Stardust" gastric mucosa in the course of immune checkpoint inhibitor-associated gastritis.Okamoto A, Yoshii S, Tsujii Y, Hayashi Y, Shinzaki S, Takehara T.Am J Gastroenterol. 2022 Oct 1;117(10):1555.
Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.Murai K, Kodama T, Hikita H, Shimoda A, Fukuoka M, Fukutomi K, Shigeno S, Shiode Y, Motooka D, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Tahata Y, Makino Y, Yamada R, Sakamori R, Tatsumi T, Takehara T.Hepatol Commun. 2022 Sep;6(9):2474-2487.
Initial drainage-related prognostic factors for perihilar cholangiocarcinoma: A single-center retrospective study.Sato K, Shigekawa M, Kozumi K, Okabe J, Sato Y, Tamura T, Yoshioka T, Sakamori R, Iwagami Y, Yamada D, Tomimaru Y, Noda T, Takahashi H, Kobayashi S, Eguchi H, Tatsumi T, Takehara T.DEN open. 2022 May 22;3(1):e127.
Hepatocellular Carcinoma in a Patient with Tetralogy of Fallot: A Case Report and Literature Review.Hyun Sung J, Sakamori R, Yamada R, Yoshioka T, Sakane S, Tahata Y, Shigekawa M, Kodama T, Hikita H, Tatsumi T, Takehara T.Intern Med. 2022 May 1;61(9):1361-1365.
Exacerbation of non-steroidal anti-inflammatory drug-induced enteropathy in C-C chemokine receptor type 7-deficient mice.Yamaguchi T, Iijima H, Yoshihara T, Tani M, Otake Y, Iwatani S, Amano T, Tashiro T, Kurahashi T, Inoue T, Tsujii Y, Hayashi Y, Inoue T, Motooka D, Nakamura S, Shinzaki S, Takehara T.J Gastroenterol Hepatol. 2022 Aug;37(8):1561-1570.
Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.Shinkai K, Sakamori R, Yamada R, Tahata Y, Nozaki Y, Matsumoto K, Tawara S, Fukuda K, Yoshida Y, Tanaka S, Ito T, Doi Y, Iio S, Sakakibara M, Nakanishi F, Kodama T, Hikita H, Tatsumi T, Takehara T.J Gastroenterol Hepatol. 2022 Jun;37(6):1148-1155.
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, Ohkawa K, Mita E, Iio S, Nozaki Y, Yakushijin T, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2022 Jul;52(7):630-640.
Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.Takigawa A, Sakamori R, Tahata Y, Yoshioka T, Yamada R, Kodama T, Hikita H, Yakushijin T, Ohkawa K, Hiramatsu N, Mita E, Hagiwara H, Ito T, Imai Y, Tatsumi T, Takehara T.Dig Dis Sci. 2022 Dec;67(12):5704-5711.
Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease.Amano T, Shinzaki S, Asakura A, Tashiro T, Tani M, Otake Y, Yoshihara T, Iwatani S, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Iijima H, Takehara T.Sci Rep. 2022 Mar 29;12(1):5324.
The First Transileocolic Obliteration for Refractory Esophageal Varices: A Case Report and Review of the Literature.Fujii Y, Sakamori R, Yamada R, Yoshioka T, Kodama T, Shigekawa M, Hikita H, Tanaka S, Ishida H, Mita E, Hongyo H, Higashihara H, Noda T, Eguchi H, Tatsumi T, Takehara T.Intern Med. 2022 Mar 15;61(6):835-839.
The degree of mucosal atrophy is associated with post-endoscopic submucosal dissection bleeding in early gastric cancer.Hayashi Y, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, Tsuji S, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Miyake A, Fujishiro M, Masamune A, Takehara T.J Gastroenterol Hepatol. 2022 May;37(5):870-877.
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, Imai Y, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T.Cancers (Basel). 2022 Feb 10;14(4):883.
TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiation.Shiode Y, Kodama T, Shigeno S, Murai K, Tanaka S, Newberg JY, Kondo J, Kobayashi S, Yamada R, Hikita H, Sakamori R, Suemizu H, Tatsumi T, Eguchi H, Jenkins NA, Copeland NG, Takehara T.Hepatology. 2023 Feb 1;77(2):395-410.
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals.Uehara S, Higuchi Y, Yoneda N, Kawai K, Yamamoto M, Kamimura H, Iida Y, Oshimura M, Kazuki Y, Yamazaki H, Hikita H, Takehara T, Suemizu H.Drug Metab Pharmacokinet. 2022 Feb;42:100410.
The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.Sakamori R, Yamada R, Tahata Y, Kodama T, Hikita H, Tatsumi T, Yamada T, Takehara T.J Gastroenterol. 2022 Feb;57(2):111-119.
Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.J Gastroenterol. 2022 Feb;57(2):120-132.
Clinical and Histopathological Features of the Differentiated Type of Early Gastric Cancer with an Unclear Lateral Demarcation.Nagai K, Hayashi Y, Uema R, Inoue T, Kimura K, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.Digestion. 2022;103(5):347-356.

2021年

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Ohkawa K, Miyazaki M, Mita E, Ito T, Hagiwara H, Yakushijin T, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2022 Mar;52(3):298-307.
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T.Aliment Pharmacol Ther. 2022 Feb;55(4):422-433.
Treatment progress and expansion in Japan: From interferon to direct-acting antiviral.Tahata Y, Sakamori R, Takehara T.Glob Health Med. 2021 Oct 31;3(5):321-334.
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum.Aliment Pharmacol Ther. 2021 Nov;54(10):1340-1349.
Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.Urabe M, Hikita H, Saito Y, Kudo S, Fukumoto K, Mizutani N, Myojin Y, Doi A, Sato K, Sakane S, Makino Y, Kodama T, Sakamori R, Tatsumi T, Takehara T.Hepatol Commun. 2022 Feb;6(2):411-422.
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.J Gastroenterol. 2021 Nov;56(11):951-963.
Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma.Amano T, Iijima H, Shinzaki S, Tashiro T, Iwatani S, Tani M, Otake Y, Yoshihara T, Sugimoto A, Egawa S, Yamaguchi S, Kinoshita K, Araki M, Hirao M, Sakakibara Y, Hiyama S, Ogawa H, Nagaike K, Murata J, Komori M, Okuda Y, Kizu T, Tsujii Y, Hayashi Y, Inoue T, Takahashi H, Mizushima T, Morii E, Takehara T.BMC Cancer. 2021 Aug 31;21(1):978.
Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration.Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.Hepatol Commun. 2022 Feb;6(2):281-296.
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T.Hepatology. 2021 Nov;74(5):2452-2466.
The First Case of Coil Embolization for Left Gastric Vein Aneurysm with Liver Cirrhosis: A Case Report and Review of the Literature.Kato S, Sakamori R, Yamada R, Murai K, Yoshioka T, Tahata Y, Shigekawa M, Kodama T, Hikita H, Hongyo H, Ono Y, Higashihara H, Tatsumi T, Takehara T.Intern Med. 2021 Aug 15;60(16):2617-2622.
Geriatric nutritional risk index as a prognostic indicator in elderly patients with early colorectal cancer undergoing endoscopic submucosal dissection.Kato M, Hayashi Y, Fukuda H, Yamaguchi S, Inoue T, Ogiyama H, Kitamura S, Komori M, Yamamoto K, Yamamoto M, Nagai K, Nakahara M, Egawa S, Yamada T, Sasakawa A, Kizu T, Nishiyama O, Shichijo S, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.Dig Endosc. 2022 Mar;34(3):569-578.
Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation.Tamura T, Kodama T, Sato K, Murai K, Yoshioka T, Shigekawa M, Yamada R, Hikita H, Sakamori R, Akita H, Eguchi H, Johnson RL, Yokoi H, Mukoyama M, Tatsumi T, Takehara T.J Clin Invest. 2021 Jul 1;131(13):e143414.
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.J Gastroenterol. 2021 Jul;56(7):593-619.
Evidence-based clinical practice guidelines for liver cirrhosis 2020.Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.Hepatol Res. 2021 Jul;51(7):725-749.
Gab1 in livers with persistent hepatocyte apoptosis has an antiapoptotic effect and reduces chronic liver injury, fibrosis, and tumorigenesis.Mizutani N, Hikita H, Saito Y, Myojin Y, Sato K, Urabe M, Kurahashi T, Shiode Y, Sakane S, Murai K, Nozaki Y, Kodama T, Sakamori R, Yoshida Y, Tatsumi T, Takehara T.Am J Physiol Gastrointest Liver Physiol. 2021 Jun 1;320(6):G958-G968.
Hepatitis C virus modulates signal peptide peptidase to alter host protein processing.Hirano J, Yoshio S, Sakai Y, Songling L, Suzuki T, Itoh Y, Zhang H, Chen DV, Haga S, Oomori H, Kodama T, Maeda Y, Ono Y, Takahashi Y, Standley DM, Yamamoto M, Moriishi K, Moriya K, Kanto T, Takehara T, Koike K, Matsuura Y, Okamoto T.Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):e2026184118.
Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T.J Gastroenterol. 2021 Jun;56(6):560-569.
Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.Myojin Y, Hikita H, Sugiyama M, Sasaki Y, Fukumoto K, Sakane S, Makino Y, Takemura N, Yamada R, Shigekawa M, Kodama T, Sakamori R, Kobayashi S, Tatsumi T, Suemizu H, Eguchi H, Kokudo N, Mizokami M, Takehara T.Gastroenterology. 2021 Apr;160(5):1741-1754.e16.
Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.Maesaka K, Sakamori R, Yamada R, Tahata Y, Ohkawa K, Oshita M, Tamura S, Hagiwara H, Mita E, Yakushijin T, Inada M, Kodama T, Hikita H, Tatsumi T, Takehara T.Anticancer Res. 2021 Apr;41(4):2187-2192.
Rebleeding in patients with delayed bleeding after endoscopic submucosal dissection for early gastric cancer.Hashimoto M, Hatta W, Tsuji Y, Yoshio T, Yabuuchi Y, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Fujishiro M, Masamune A, Ohira H; Collaborators.Dig Endosc. 2021 Nov;33(7):1120-1130.
Use of a convolutional neural network for classifying microvessels of superficial esophageal squamous cell carcinomas.Uema R, Hayashi Y, Tashiro T, Saiki H, Kato M, Amano T, Tani M, Yoshihara T, Inoue T, Kimura K, Iwatani S, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T.J Gastroenterol Hepatol. 2021 Aug;36(8):2239-2246.
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.Maesaka K, Sakamori R, Yamada R, Tahata Y, Oshita M, Hagiwara H, Sakakibara M, Tamura S, Hiramatsu N, Inada M, Iio S, Ito T, Yakushijin T, Doi Y, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2021 May;51(5):517-527.
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis: A Case Report.Sakamori R, Yamada R, Shinkai K, Doi A, Tahata Y, Shigekawa M, Kodaa T, Hikita H, Yamada T, Tatsumi T, Takehara T.Intern Med. 2021;60(5):745-750.
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.Myojin Y, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, Abe Y, Ohkawa K, Mita E, Hayashi Y, Hikita H, Sakamori R, Tatsumi T, Taguchi A, Eguchi H, Takehara T.Clin Cancer Res. 2021 Feb 15;27(4):1150-1161.
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.Nozaki Y, Hikita H, Tanaka S, Fukumoto K, Urabe M, Sato K, Myojin Y, Doi A, Murai K, Sakane S, Saito Y, Kodama T, Sakamori R, Tatsumi T, Takehara T.Sci Rep. 2021 Feb 9;11(1):3363.
Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M.J Gastroenterol Hepatol. 2021 Jul;36(7):1744-1753.
Helicobacter pylori eradication prevents secondary gastric cancer in patients with mild-to-moderate atrophic gastritis.Kato M, Hayashi Y, Nishida T, Oshita M, Nakanishi F, Yamaguchi S, Kitamura S, Nishihara A, Akasaka T, Ogiyama H, Nakahara M, Yamada T, Kishida O, Yamamoto M, Shimayoshi A, Tsujii Y, Kato M, Shinzaki S, Iijima H, Takehara T.J Gastroenterol Hepatol. 2021 Aug;36(8):2083-2090.
Suppression of autophagy promotes fibroblast activation in p53-deficient colorectal cancer cells.Inoue T, Hayashi Y, Tsujii Y, Yoshii S, Sakatani A, Kimura K, Uema R, Kato M, Saiki H, Shinzaki S, Iijima H, Takehara T.Sci Rep. 2021 Sep 30;11(1):19524.
Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis.Motooka K, Morishita K, Ito N, Shinzaki S, Tashiro T, Nojima S, Shimizu K, Date M, Sakata N, Yamada M, Takamatsu S, Kamada Y, Iijima H, Mizushima T, Morii E, Takehara T, Miyoshi E.World J Gastroenterol. 2021 Jan 14;27(2):162-175.
White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.Sakane S, Hikita H, Shirai K, Myojin Y, Sasaki Y, Kudo S, Fukumoto K, Mizutani N, Tahata Y, Makino Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.Cell Mol Gastroenterol Hepatol. 2021;12(5):1683-1699.
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T.Liver Cancer. 2021 Jun;10(3):181-223.

2020年

"Floating" method and "lifting up" method: novel techniques of gastric endoscopic submucosal dissection for treating difficult-to-approach lesions.Yoshii S, Hayashi Y, Uema R, Tsujii Y, Iijima H, Takehara T.Endoscopy. 2021 Sep;53(9):E324-E325.
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: A Japanese real-world multicenter study.Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.J Gastroenterol. 2021 Jan;56(1):67-77.
Endoscopic biliary stenting as the risk factor for cholangitis after endoscopic ultrasound in patients with biliary strictures.Ikezawa K, Shigekawa M, Yamai T, Suda T, Kegasawa T, Yoshioka T, Sakamori R, Tatsumi T, Takehara T.J Gastroenterol Hepatol. 2021 May;36(5):1263-1266.
Detection of Phosphorylated Alpha-Synuclein in the Muscularis Propria of the Gastrointestinal Tract Is a Sensitive Predictor for Parkinson's Disease.Beck G, Hori Y, Hayashi Y, Morii E, Takehara T, Mochizuki H.Parkinsons Dis. 2020 Sep 23;2020:4687530.
Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation.Shiode Y, Hikita H, Tanaka S, Shirai K, Doi A, Sakane S, Kai Y, Nakabori T, Yamada R, Kodama T, Narumi R, Sakamori R, Eguchi H, Tomonaga T, Tatsumi T, Takehara T.Sci Rep. 2020 Sep 17;10(1):15290.
Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Oshita M, Ohkawa K, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2020 Nov;50(11):1275-1283.
Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.Maesaka K, Sakamori R, Yamada R, Urabe A, Tahata Y, Oshita M, Ohkawa K, Mita E, Hagiwara H, Tamura S, Ito T, Yakushijin T, Iio S, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2020 Sep;50(9):1091-1100.
Clinical outcomes of direct-acting antiviral treatments for hepatitis C patients after hepatocellular carcinoma are equivalent to interferon treatment.Tahata Y, Sakamori R, Urabe A, Yamada R, Ohkawa K, Hiramatsu N, Hagiwara H, Oshita M, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2020 Oct;50(10):1118-1127.
Prophylactic clipping not effective in preventing post-polypectomy bleeding for < 20-mm colon polyps: A multicenter, open-label, randomized controlled trial.Inoue T, Ishihara R, Nishida T, Akasaka T, Hayashi Y, Nakamatsu D, Ogiyama H, Yamaguchi S, Yamamoto K, Mukai A, Kinoshita K, Yakushijin T, Iijima H, Takehara T.J Gastroenterol Hepatol. 2021 Feb;36(2):383-390.
Oligosaccharide-dependent anti-inflammatory role of galectin-1 for macrophages in ulcerative colitis.Iwatani S, Shinzaki S, Amano T, Otake Y, Tani M, Yoshihara T, Tsujii Y, Hayashi Y, Inoue T, Okuzaki D, Mizushima T, Miyoshi E, Iijima H, Takehara T.J Gastroenterol Hepatol. 2020 Dec;35(12):2158-2169.
Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.Sato K, Hikita H, Myojin Y, Fukumoto K, Murai K, Sakane S, Tamura T, Yamai T, Nozaki Y, Yoshioka T, Kodama T, Shigekawa M, Sakamori R, Tatsumi T, Takehara T.PLoS One. 2020 Jul 1;15(7):e0235573.
Lower serum sodium levels are associated with the therapeutic effect of sorafenib on hepatocellular carcinoma.Kegasawa T, Sakammori R, Maesaka K, Yamada R, Tahata Y, Urabe A, Kodama T, Hikita H, Imanaka K, Ohkawa K, Hiramatsu N, Oshita M, Yamada Y, Inada M, Yakushijin T, Imai Y, Tatsumi T, Takehara T.Dig Dis Sci. 2021 May;66(5):1720-1729.
Pre-existing Minor Variants With NS5A L31M/V-Y93H Double Substitution Are Closely Linked to Virologic Failure With Asunaprevir Plus Daclatasvir Treatment for Genotype 1b Hepatitis C Virus Infection.Morishita N, Sakamori R, Yamada T, Kai Y, Tahata Y, Urabe A, Yamada R, Kodama T, Hikita H, Doi Y, Tamura S, Hagiwara H, Imai Y, Iio S, Tatsumi T, Takehara T.PLoS One. 2020 Jun 16;15(6):e0234811.
Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study.Kamada Y, Morishita K, Koseki M, Nishida M, Asuka T, Naito Y, Yamada M, Takamatsu S, Sakata Y, Takehara T, Miyoshi E.Nutrients. 2020 Jun 12;12(6):1770.
Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score.Hatta W, Tsuji Y, Yoshio T, Kakushima N, Hoteya S, Doyama H, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Koike T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Nakamura T, Nakaya N, Fujishiro M, Masamune A.Gut. 2020 Jun 4:gutjnl-2019-319926.
SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy.Yamai T, Hikita H, Fukuoka M, Fukutomi K, Murai K, Nakabori T, Yamada R, Miyakawa K, Watashi K, Ryo A, Kodama T, Sakamori R, Tatsumi T, Takehara T.Biochem Biophys Res Commun. 2020 Jun 18;527(1):64-70.
Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 production.Kamada Y, Yamamoto A, Fujiyoshi A, Koseki M, Morishita K, Asuka T, Takamatsu S, Sakata Y, Takehara T, Taniguchi N, Miyoshi E.Biochem Biophys Res Commun. 2020 Jun 30;527(3):682-688.
Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study.Araki M, Shinzaki S, Yamada T, Arimitsu S, Komori M, Shibukawa N, Mukai A, Nakajima S, Kinoshita K, Kitamura S, Murayama Y, Ogawa H, Yasunaga Y, Oshita M, Fukui H, Masuda E, Tsujii M, Kawai S, Hiyama S, Inoue T, Tanimukai H, Takehara T.PLoS One. 2020 May 26;15(5):e0233365.
Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group.Hepatol Int. 2020 Jul;14(4):478-482.
Clinical course and risk factors for mortality of COVID-19 patients with preexisting cirrhosis: a multicentre cohort study.Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Li X, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Li X, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Li X, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rockey DC; COVID-Cirrhosis-CHESS Group.Gut. 2021 Feb;70(2):433-436.
Novel mass spectrometry-based comprehensive lipidomic analysis of plasma from patients with inflammatory bowel disease.Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, Tashiro T, Tsujii Y, Inoue T, Hayashi Y, Takeda K, Hayashi A, Fujita S, Shinzaki S, Takehara T.J Gastroenterol Hepatol. 2020 Aug;35(8):1355-1364.
Risk Factors for Pancreatic Cancer and the Necessity of Long-term Surveillance in Patients With Pancreatic Cystic Lesions.Yoshioka T, Shigekawa M, Ikezawa K, Tamura T, Sato K, Urabe M, Sueyoshi H, Yamai T, Suda T, Sakamori R, Tatsumi T, Takehara T.Pancreas. 2020 Apr;49(4):552-560.
Efficacy of vonoprazan for the prevention of bleeding after gastric endoscopic submucosal dissection with continuous use of antiplatelet agents.Yoshii S, Yamada T, Yamaguchi S, Hayashi Y, Nakahara M, Shibukawa N, Yamamoto M, Ishihara R, Kinoshita K, Egawa S, Tsujii Y, Iijima H, Takehara T.Endosc Int Open. 2020 Apr;8(4):E481-E487.
Usefulness of a dedicated mouthpiece for the Valsalva maneuver to visualize the hypopharynx during transoral endoscopy.Kato M, Hayashi Y, Uema R, Saiki H, Kimura K, Inoue T, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Hida E, Iijima H, Takehara T.Endosc Int Open. 2020 Apr;8(4):E536-E543.
JNJ-4178 (Adafosbuvir, Odalasvir, and Simeprevir) in Japanese Patients With Chronic Hepatitis C Virus Genotype 1 or 2 Infection With or Without Compensated Cirrhosis: The Phase IIa OMEGA-3 Study.Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Michael B, Leen V, Hayashi N.J Gastroenterol. 2020 Jun;55(6):640-652.
Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.Murai K, Hikita H, Kai Y, Kondo Y, Fukuoka M, Fukutomi K, Doi A, Yamai T, Nakabori T, Fukuda R, Takahashi T, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T.Sci Rep. 2020 Jan 22;10(1):941.
Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.Tahata Y, Sakamori R, Urabe A, Yamada R, Ohkawa K, Hiramatsu N, Hagiwara H, Oshita M, Hijioka T, Tamura S, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T.Hepatol Res. 2020 Mar;50(3):313-320.
Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice.Kurahashi T, Yoshida Y, Ogura S, Egawa M, Furuta K, Hikita H, Kodama T, Sakamori R, Kiso S, Kamada Y, Wang IC, Eguchi H, Morii E, Doki Y, Mori M, Kalinichenko VV, Tatsumi T, Takehara T.Cell Mol Gastroenterol Hepatol. 2020;9(3):425-446.